Anondita Medicare Ltd
Anondita Medicare Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #1 of 7 in Personal Products
See the sector's top 10 — free with your mobile number.
Anondita Medicare Ltd Q4 FY26 key numbers
- Revenue
- Anticipates doubling revenue to INR 1,000 crores within the next 2 years.
As stated in Anondita Medicare Ltd's Q4 FY26 earnings call transcript · published 26 Sept 2026. Reported figures, not investment advice.
The short version
Company expects major revenue growth driven by increased capacities and international market expansion. Revenue is expected to reach INR1,000 crores within the next 2 years, implying around 100% year-on-year growth.
From Anondita Medicare Ltd's Q4 FY26 earnings-call transcript · updated 26 Sept 2026.
Revenue & Sales Performance
- Company expects major revenue growth driven by increased capacities and international market expansion.
- Total manufacturing capacity increased from 562 million to 806 million condoms annually, with initial utilization expected around 75%.
- Anticipates doubling revenue to INR 1,000 crores within the next 2 years.
- Expects 25% capacity addition to contribute INR 325 crores turnover in the coming year.
- Focus on export markets including South Africa (1 billion pieces tender over 5 years), Brazil, and others, to drive volume growth.
- Plans to launch innovative products (spiral condoms, non-latex male condoms, female condoms) to capture market share.
- Government business expected to grow moderately (~5-10%), but primary focus on own brand "Cobra" and exports with higher margins.
2 more points from Anondita Medicare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anondita Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company undertook significant capex in FY 2026, adding to property, plant, and equipment, with CWIP also increased.
- Total capex done last year was approximately INR 62 crores; out of that, INR 24 crores was already spent, expanding capacity to 307 million units.
- Additional capacity under WIP is expected to increase capacity by 250 million units, aiming for a turnover of around INR 325 crores from this expansion.
- The capex was completed by end of December, so depreciation expense impact in FY 2026 was limited to one quarter.
- The company has patented in-house manufacturing machines, which facilitate faster and lower-cost capacity expansion compared to competitors.
2 more points from Anondita Medicare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Personal Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anondita Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Current unexecuted order book stands at approximately INR137 crores, which remains intact from the previous year.
- The company has secured a single rate contract as the sole L1 supplier to the Government of India National AIDS Control Society, ensuring continuous government orders.
- Registered in South Africa for the next five years with a requirement of 1 billion pieces annually; expects to execute about 25% of that order this year, leading to significant revenue jump.
- Order pipeline includes international orders from countries like Kenya, Uzbekistan, Brazil, and South Africa under their own brand "Cobra."
2 more points from Anondita Medicare Ltd's call on order book
Create a free account to keep reading this call
What the Q4 FY26 call signalled
4 of 4 strong
Continue your research
What Anondita Medicare's management said in earlier quarters
Others in Personal Products this season
- Recode Studios (Q4 FY26)
The company plans to sustain marketing spends at about 20% of revenue to support growth and brand visibility, implying continued focus on operating profits…
- Cupid (Q4 FY26)
Q4 FY26 Revenue from operations: ₹119.96 Cr, up 112.39% YoY from ₹56.48 Cr in Q4 FY25 (Page 18). Key concall takeaways from Cupid Ltd's Q4 FY26 earnings call…
- Bajaj Consumer (Q4 FY26)
Revenue growth momentum is strong, with a 21% increase for the full year FY26 and a 30% top-line growth noted in Q4. Key concall takeaways from Bajaj Consumer…
- Godrej Consumer (Q4 FY26)
Operating metrics such as ARR for Fab portfolio (~INR 500 crores GSV). Key concall takeaways from Godrej Consumer's Q4 FY26 earnings call — and how it ranks…
Potential multibaggers · Q2 FY27
Potential multibaggers in Personal Products
on management's own guidance
- Strong growth2
- 1
- EmamiGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anondita Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anondita Medicare Ltd Q4 FY26 results?
Company expects major revenue growth driven by increased capacities and international market expansion. Revenue is expected to reach INR1,000 crores within the next 2 years, implying around 100% year-on-year growth.
What is Anondita Medicare Ltd share price analysis?
Anondita Medicare Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 62.1 with a market cap of ₹2,077 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anondita Medicare Ltd planning capital expenditure?
The company undertook significant capex in FY 2026, adding to property, plant, and equipment, with CWIP also increased.
Keep Anondita Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.